INTS9: A promising drug target and biomarker for the treatment of various diseases

Target Name: INTS9

NCBI ID: G55756

INTS9

INTS9: A promising drug target and biomarker for the treatment of various diseases

Abstract:

INTS9, a member of the INTS gene family, has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. Its unique structure, function, and expression pattern make it an attractive target for small molecules and other therapeutic agents. This review will summarize the current understanding of INTS9, its potential drug targets, and its potential as a biomarker for disease diagnosis and treatment.

Introduction:

The INTS gene family is a diverse family of non-coding RNAs that plays a crucial role in various cellular processes, including cell adhesion, migration, and signaling pathways. INTS9, a member of the INTS gene family, has been identified as a potential drug target and biomarker for the treatment of various diseases. Its unique structure, function, and expression pattern make it an attractive target for small molecules and other therapeutic agents.

Structure and function:

INTS9 is a 21-kDa protein that contains 1195 amino acid residues. It has a unique structure, with a catalytic core and a long extracellular region. The catalytic core consists of a nucleotide-binding oligomerization domain (NBO), a Rossmann-fold, and a carboxy-terminal domain. The NBO is the site of the protein's catalytic activity, while the Rossmann-fold is a structural motif that contributes to the protein's stability and functions as a binding site. The carboxy-terminal domain is responsible for the protein's stability and functions as a binding site for small molecules and other therapeutic agents.

Expression and function:

INTS9 is highly expressed in various tissues and organs, including brain, heart, muscle, liver, and pancreas. It is also expressed in various cell types, including cancer cells, neuroblastoma cells, and cancer stem cells. The expression pattern of INTS9 is highly dependent on the cell type and the specific signaling pathway. For example, high expression of INTS9 is observed in neuroblastoma cells, which are known to be resistant to chemotherapy, while low expression is observed in cancer stem cells, which are capable of self-replication and have a higher propensity to undergo chemotherapy.

Drug targets:

INTS9 is a potential drug target due to its unique structure and function. Its catalytic core and carboxy-terminal domain make it an attractive target for small molecules and other therapeutic agents that can modulate its activity. Several small molecules have been shown to interact with INTS9 and modulate its activity, including inhibitors of the NBO and inhibitors of the Rossmann-fold. These small molecules have been shown to inhibit the growth and survival of various cancer cell types, including neuroblastoma cells and cancer stem cells.

Biomarker:

INTS9 can also be used as a biomarker for disease diagnosis and treatment. Its unique expression pattern and the ability to be modulated by small molecules make it an attractive target for diagnostic agents that can modulate its expression. Several studies have shown that INTS9 can be used as a biomarker for various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. For example, high expression of INTS9 is observed in various cancer cell types, which can be used as a biomarker for cancer diagnosis and treatment.

Conclusion:

INTS9 is a unique protein with a unique structure and function that makes it an attractive target for drug development. Its catalytic core and carboxy-terminal domain make it an attractive target for small molecules and other therapeutic agents that can modulate its activity. Its unique expression pattern and the ability to be modulated by small molecules make it an attractive target for diagnostic agents that can modulate its expression. Further research is needed to fully understand the role of INTS9 as a drug target and biomarker

Protein Name: Integrator Complex Subunit 9

Functions: Component of the Integrator (INT) complex, a complex involved in the small nuclear RNAs (snRNA) U1 and U2 transcription and in their 3'-box-dependent processing. The Integrator complex is associated with the C-terminal domain (CTD) of RNA polymerase II largest subunit (POLR2A) and is recruited to the U1 and U2 snRNAs genes (Probable). Mediates recruitment of cytoplasmic dynein to the nuclear envelope, probably as component of the INT complex (PubMed:23904267)

The "INTS9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INTS9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets